Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
$1.36
$1.25
$11.80
$2.54M2.37127,289 shs23,000 shs
Dyadic International Inc. stock logo
DYAI
Dyadic International
$0.93
-1.0%
$1.03
$0.91
$2.20
$28.28M0.8854,873 shs112,279 shs
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$3.10
$4.66
$0.30
$1.47
$105.77M2.6993,510 shsN/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
$7.30
+0.7%
$2.06
$0.26
$3.77
$191.84M2.06168,718 shs73,796 shs
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
$1.07
$1.01
$0.56
$1.43
$65.08M1.75430,375 shsN/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Dyadic International Inc. stock logo
DYAI
Dyadic International
0.00%-6.80%-4.71%-25.52%-36.67%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00%0.00%0.00%0.00%0.00%
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
0.00%+9.77%+9.28%+5.95%+26.96%
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Dyadic International Inc. stock logo
DYAI
Dyadic International
1.9943 of 5 stars
3.54.00.00.00.01.70.0
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
1.4315 of 5 stars
0.04.00.04.70.60.80.6
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
0.00
N/AN/AN/A
Dyadic International Inc. stock logo
DYAI
Dyadic International
3.00
Buy$6.00544.47% Upside
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00
N/AN/AN/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
0.00
N/AN/AN/A
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/AN/AN/AN/A($3.81) per shareN/A
Dyadic International Inc. stock logo
DYAI
Dyadic International
$3.49M8.03N/AN/A$0.08 per share11.64
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$32.66M3.24N/AN/A$0.80 per share3.88
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
$287M0.67N/AN/A$8.96 per share0.81
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
$30M2.17N/AN/A$0.81 per share1.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/A
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$5.81M-$0.20N/AN/AN/A-163.94%-233.69%-59.37%8/12/2025 (Estimated)
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
-$240KN/A0.00N/AN/AN/AN/AN/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
-$317M-$5.79N/AN/A-141.03%-81.98%-52.13%N/A
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
-$63.59M-$1.53N/AN/AN/AN/A-107.81%-65.57%N/A

Latest SURF, DYAI, BVXV, LOGC, and ERYP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Dyadic International Inc. stock logo
DYAI
Dyadic International
N/A-$0.07N/A-$0.07N/A$0.39 million
5/9/2025Q1 2025
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
N/A-$0.27N/A-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/AN/AN/AN/AN/A
Dyadic International Inc. stock logo
DYAI
Dyadic International
N/AN/AN/AN/AN/A
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
N/AN/AN/AN/AN/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
N/AN/AN/AN/AN/A
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/A
4.12
4.12
Dyadic International Inc. stock logo
DYAI
Dyadic International
5.40
3.98
3.98
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.32
3.65
3.65
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
N/A
31.60
31.60
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
N/A
3.60
3.60
CompanyEmployeesShares OutstandingFree FloatOptionable
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
331.87 million1.76 millionNot Optionable
Dyadic International Inc. stock logo
DYAI
Dyadic International
730.09 million21.21 millionOptionable
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
4934.12 million33.46 millionNot Optionable
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
6226.28 million24.16 millionOptionable
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
3560.82 million53.53 millionNot Optionable

Recent News About These Companies

Q3 2024 Heron Therapeutics Inc Earnings Call
How wearable tech can help women fight breast cancer

New MarketBeat Followers Over Time

Media Sentiment Over Time

BiondVax Pharmaceuticals stock logo

BiondVax Pharmaceuticals NASDAQ:BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Dyadic International stock logo

Dyadic International NASDAQ:DYAI

$0.93 -0.01 (-0.96%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$0.95 +0.02 (+1.83%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

ERYTECH Pharma stock logo

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

LogicBio Therapeutics stock logo

LogicBio Therapeutics NASDAQ:LOGC

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Surface Oncology stock logo

Surface Oncology NASDAQ:SURF

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.